申请人:AGIOS PHARMACEUTICALS, INC.
                            
                            
                                公开号:US20210323944A1
                            
                            
                                公开(公告)日:2021-10-21
                            
                            Provided are formulations of ivosidenib including a number of polymorphs. Further provided are formulations of ivosidenib containing a number of known impurities. Still further provided are stable compositions of ivosidenib.